Enrolment for the two-dose recombinant DNA vaccine complete. Data expected by end-February, post which filing to be done with Indian regulator
Received order from Indian government to supply 10 million doses of the three-dose recombinant DNA vaccine, Zy-CoV-D, which is already approved (Also see "Is India’s Budget Bad News For COVID-19 Boosters, New Vaccines?" - Scrip, 4 February, 2022.)
Supplies to be made to government in Q4 FY22 and Q1 FY23 at 265 per dose for vaccine + 93 per dose for applicator + GST. So, for 3 doses it would be INR 1074 + GST
Pricing in the private market to be higher government pricing, but expected to be more competitive than current players
Lancet has accepted submission of interim analysis of Phase III clinical trial results for ZyCoV-D vaccine for publication.
WHO pre-qualification expected to be sought post publication of results in Lancet and after stability in production of drug substance and drug products is reached
Partner Enzychem Lifesciences Corporationof South Korea seen producing over 80 million doses of Zy-CoV-D2 in 2022. These doses will be supplied in South Korea and other countries in Latin America and Asia.

Zydus Claims Top Spot In India Biosimilars With Kadcyla, Sees 40-50% Growth

Single-Dose Malaria Drug Moves To Phase II